Han-dong Wang

Prof. Han-dong Wang

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
KDKe Ding
Ke Ding
HWHan-dong Wang
Han-dong Wang
JXJianguo Xu
Jianguo Xu
TLTao Li
Tao Li
LZLi Zhang
Li Zhang
MZMeng-liang Zhou
Meng-liang Zhou

1 June 2014 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
JXJianguo Xu
Jianguo Xu
HWHan-dong Wang
Han-dong Wang
KDKe Ding
Ke Ding
LZLi Zhang
Li Zhang
CWChunxi Wang
Chunxi Wang
XLXinyu Lu
Xinyu Lu

14 July 2015 in Marine Drugs
Verified
Journal Article
Open access
PDF file
LZLi Zhang
Li Zhang
HWHan-dong Wang
Han-dong Wang
Astaxanthin (ATX) is a xanthophyll carotenoid which has been approved by the United States Food and Drug Administration (USFDA) as food colorant in animal and fish feed. It is widely found in algae and aquatic animals and has powerful anti-oxidative activity. Previous studies have revealed that ATX, with its anti-oxidative property, is beneficial as a therapeutic agent for various diseases without any side effects or toxicity. In addition, ATX also shows preclinical anti-tumor efficacy both in vivo and in vitro in various cancer models. Several researches have deciphered that ATX exerts its anti-proliferative, anti-apoptosis and anti-invasion influence via different molecules and pathways including signal transducer and activator of transcription 3 (STAT3), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and peroxisome proliferator-activated receptor gamma (PPARγ). Hence, ATX shows great promise as chemotherapeutic agents in cancer. Here, we review the rapidly advancing field of ATX in cancer therapy as well as some molecular targets of ATX.

21 April 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LZLi Zhang
Li Zhang
HWHan-dong Wang
Han-dong Wang
YFYouwu Fan
Youwu Fan
YGYongyue Gao
Yongyue Gao
XLXiang Li
Xiang Li
XWXiaoliang Wang
Xiaoliang Wang
Fucoxanthin is abundant in seaweed and is considered as a powerful antioxidant. It has been proposed to possess anti-cancer, anti-obesity and anti-diabetes effects. However, its roles in brain injury models have not been fully understood. The objective of this study was to investigate the neuroprotection of fucoxanthin in models of traumatic brain injury (TBI) and the role of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant-response element (ARE) and Nrf2-autophagy pathways in the putative neuroprotection. We found that fucoxanthin alleviated TBI-induced secondary brain injury, including neurological deficits, cerebral edema, brain lesion and neuronal apoptosis. Moreover, the up-regulation of malondialdehyde (MDA) and the activity of glutathione peroxidase (GPx) were reversed by fucoxanthin treatment. Furthermore, our in vitro studies demonstrated that fucoxanthin increased the neuron survival and reduced the reactive oxygen species (ROS) level. In addition, fucoxanthin activated the Nrf2-ARE pathway and autophagy both in vivo and in vitro, which was proven by the results of immunohistochemistry, western blot and electrophoretic mobility shift assay (EMSA). However, fucoxanthin failed to provide neuroprotection and activated autophagy following TBI in Nrf2−/− mice. In conclusion, our studies indicated that fucoxanthin provided neuroprotective effects in models of TBI, potentially via regulation of the Nrf2-ARE and Nrf2-autophagy pathways.

18 December 2014 in Marine Drugs
Verified
Journal Article
Open access
PDF file
QWQi Wu
Qi Wu
XZXiangsheng Zhang
Xiangsheng Zhang
HWHan-dong Wang
Han-dong Wang
XZXin Zhang
Xin Zhang
QYQing Yu
Qing Yu
XWXiao-Liang Wang
Xiao-Liang Wang
Astaxanthin (ATX) has been proven to ameliorate early brain injury (EBI) after experimental subarachnoid hemorrhage (SAH) by modulating cerebral oxidative stress. This study was performed to assess the effect of ATX on the Nrf2-ARE pathway and to explore the underlying molecular mechanisms of antioxidant properties of ATX in EBI after SAH. A total of 96 male SD rats were randomly divided into four groups. Autologous blood was injected into the prechiasmatic cistern of the rat to induce an experimental SAH model. Rats in each group were sacrificed at 24 h after SAH. Expressions of Nrf2 and heme oxygenase-1 (HO-1) were measured by Western blot and immunohistochemistry analysis. The mRNA levels of HO-1, NAD (P) H: quinone oxidoreductase 1 (NQO-1), and glutathione S-transferase-α1 (GST-α1) were determined by real-time polymerase chain reaction (PCR). It was observed that administration of ATX post-SAH could up-regulate the cortical expression of these agents, mediated in the Nrf2-ARE pathway at both pretranscriptional and posttranscriptional levels. Meanwhile, oxidative damage was reduced. Furthermore, ATX treatment significantly attenuated brain edema, blood–brain barrier (BBB) disruption, cellular apoptosis, and neurological dysfunction in SAH models. This study demonstrated that ATX treatment alleviated EBI in SAH model, possibly through activating the Nrf2-ARE pathway by inducing antioxidant and detoxifying enzymes.

1 August 2014 in Toxicology Letters
Verified
Journal Article
Closed access
LZLi Zhang
Li Zhang
HWHan-dong Wang
Han-dong Wang
JXJianguo Xu
Jianguo Xu
JZJianhong Zhu
Jianhong Zhu
KDKe Ding
Ke Ding